Divalproex Sodium
Product Images NDC 67296-1677

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 67296-1677). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Divalproex 1677)

Label for Divalproex Sodium ER 250 mg tablets, containing 10 tablets per package. The label shows it is an Rx-only product distributed by RedPharm Drug, Inc., Eden Prairie, MN and manufactured by Arneal Pharmaceuticals Pvt Ltd, Ahmedabad, India. It includes storage instructions to keep at 20-25°C (68-77°F) and a lot number and expiration date of 08/20.*

FDA Label Image

10 (Divalproex Sodium Extended Release Tablets Usp 1)

Chemical structure of Divalproex Sodium showing its molecular components and arrangement including sodium ion (Na+), carbon chains, and carboxylate groups.*

FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

A line graph comparing percent reduction in CPS (clinical parameter) rate between Divalproex Sodium and placebo across a percentage of patients. The y-axis shows percent reduction from -100% (worsening) to 100% (improvement) with a midpoint at no change, while the x-axis shows percent of patients from 100 to 0. The solid line represents Divalproex Sodium, and the dashed line represents placebo.*

FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

A line graph displaying the percentage reduction in CPS rate versus the percentage of patients for high dose and low dose Divalproex Sodium. The y-axis represents improvement or worsening in CPS rate, and the x-axis shows the percentage of patients, with separate lines for high dose (solid) and low dose (dashed) Divalproex Sodium responses.*

FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

A bar chart comparing two groups: Placebo and Divalproex Sodium Extended Release. The Y-axis values range from 0 to 1.2, with the Divalproex Sodium Extended Release group showing a higher value (1.2) compared to the Placebo group (0.6). A note indicates a statistical significance with p=0.006.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.